Myung‐Ju Ahn
Chungnam National University(KR)Samsung Medical Center(KR)Dana-Farber Cancer Institute(US)Sungkyunkwan University(KR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial(2015)6,477 cited
- → Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer(2015)6,153 cited
- → Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer(2013)3,387 cited
- → Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial(2019)3,269 cited
- → Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer(2016)3,266 cited
- → AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer(2015)2,095 cited